Form 483

Vivex Biologics, Inc. Form 483, 2017-07-06

FDA issued a Form 483 to Vivex Biologics, Inc. on 2017-07-06 with 4 public-safe observations.

483· Form 483 issuedBiologics4 observations

Vivex Biologics, Inc. · Miami, United States · Issued July 6, 2017

Overview

  • 4 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

6 Jul 2017
21 CFR 1271.160(b)(6)

Deviations--evaluation, cause, corrective action

Cited by Ivan E Reyes, Shavon L Square, Colleen M Aspinwall

6 Jul 2017
21 CFR 1271.230(a)

Validation & approval--established procedures

Cited by Ivan E Reyes, Shavon L Square, Colleen M Aspinwall

6 Jul 2017
21 CFR 1271.200(d)

Inspected routinely

Cited by Ivan E Reyes, Shavon L Square, Colleen M Aspinwall

6 Jul 2017
21 CFR 1271.220(a)

Causing contamination, increasing risks

Cited by Ivan E Reyes, Shavon L Square, Colleen M Aspinwall

Inspected site

VBVivex Biologics, Inc.Miami, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 1271.160(b)(6)Cited across public-safe Form 483 observations1x
21 CFR 1271.200(d)Cited across public-safe Form 483 observations1x
21 CFR 1271.220(a)Cited across public-safe Form 483 observations1x
21 CFR 1271.230(a)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 4 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere